Epilepsy Medical Cannabis UK: Beyond Epidyolex

Cannabis for Epilepsy in the UK: The Full Picture

• Epidyolex (pharmaceutical-grade CBD) is licensed in the UK for Dravet syndrome and Lennox-Gastaut syndrome.
• NICE recommends Epidyolex for eligible paediatric patients in conjunction with clobazam.
• Adult epilepsy patients and those with other seizure disorders may access unlicensed cannabis products via private clinics.
• Whole-plant cannabis products are not NICE-recommended for epilepsy but are legally prescribable by specialists.

Epilepsy affects around 600,000 people in the UK, and approximately one third have drug-resistant seizures that do not respond to conventional antiepileptic drugs. Cannabis medicines — from licensed Epidyolex to broader unlicensed products — offer an important additional option for eligible patients.

High-Profile Cases and UK Policy Change

• The cases of Alfie Dingley and Billy Caldwell in 2018 were pivotal in changing UK law to permit cannabis prescribing.
• Both children had severe drug-resistant epilepsy and experienced dramatic seizure reduction with cannabis medicines.
• Home Secretary Sajid Javid’s 2018 decision triggered the November 2018 rescheduling of cannabis-based medicines.
• These cases continue to shape public and clinical awareness of cannabis for epilepsy in the UK.

The high-profile paediatric epilepsy cases drove the fastest regulatory change in UK drugs law in recent decades. They remain important reference points for understanding the clinical rationale for cannabis-based epilepsy treatment.

Access Beyond Epidyolex for UK Epilepsy Patients

• Adults with drug-resistant epilepsy can self-refer to private UK cannabis clinics for specialist assessment.
• Some NHS paediatric neurologists now prescribe unlicensed cannabis products when Epidyolex is not available or suitable.
• Access is most straightforward for patients with documented drug-resistant epilepsy and two or more failed AED trials.
• Neurologists at specialist centres in London, Manchester, and Edinburgh are the most experienced in this area.

Beyond Epidyolex, the access landscape for UK epilepsy patients is patchy and largely dependent on local specialist willingness to prescribe. Private clinics offer a more consistent pathway but should ideally work in coordination with the patient’s existing NHS neurologist.

Costs and Practical Considerations

• Epidyolex via NHS: available at no cost for eligible paediatric patients under NICE guidance.
• Private unlicensed cannabis products for epilepsy: £100–£300 per month depending on formulation.
• Initial private specialist consultation: £150–£280; ongoing neurology review fees apply.
• Parents of children with treatment-resistant epilepsy should contact NICE and local ICBs about funding for Epidyolex.

Epilepsy patients considering medical cannabis should always do so in close collaboration with their neurologist, given the risk of interaction with existing antiepileptic medication. Abrupt changes to antiepileptic regimens can increase seizure risk and must be managed carefully.